Elimination of Minimal Residual Disease After Transplant
Status:
Not yet recruiting
Trial end date:
2027-09-15
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM)
patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell
transplant (ASCT) irrespective of the International Myeloma Working Group (IMWG) response.